Companion Medical Expands Leadership Team in Preparation for Commercial Launch
Key technical and sales leaders strengthen Companion's approaching launch of the first smart insulin delivery system in the U.S.
May 31, 2017, 11:00 ET
SAN DIEGO, May 31, 2017 /PRNewswire/ -- Companion Medical, a leader in the development of advanced technology to improve diabetes care, has announced the addition of two key executives. Michael Mensinger, a board member, early investor and co-founder of Companion, joins the company as Chief Technology Officer from Dexcom where he led their app and cloud software teams. Mensinger is a seasoned engineering leader with a history of first-in-class products in diabetes. Tony Galliani joins the company as National Sales Director from Tandem Diabetes Care where he served as Sales Director of the eastern United States. Tony brings 18 years of diabetes experience to the company and previously held positions at Minimed and Animas, a Johnson & Johnson company.
"I'm thrilled to announce the addition of these two experienced leaders to our organization," said Sean Saint, CEO. "Mike and I had the original discussions which led to the founding of Companion Medical, and his technical leadership positions us well as we move into more sophisticated smart technologies. On the sales front, Tony and I worked together at Tandem where he helped launch the t:slim insulin pump. The fundamental purpose of Companion's InPen is to bring the benefits of insulin pumps to pen and syringe users. Tony has a deep understanding of the issues that matter to people living with diabetes, their healthcare providers and payors."
About Companion Medical:
Companion Medical has developed the first smart insulin pen and proprietary mobile app with wireless data communication and dose calculator to help improve safety and consistency in diabetes management. The InPen® System calculates and recommends optimal insulin doses, tracks history and timing of doses, monitors insulin temperature, displays last dose and insulin-on-board, and has the capability to track and report real-time to care providers. Companion received 510(k) clearance from FDA in Q3 2016 and is preparing for U.S. market launch. Companion anticipates receiving CE Mark in 2017.
For further information, please contact:
Sean Saint, President and CEO
Email: [email protected]
Phone: 858-522-0252
InPen® is a registered trademark of Companion Medical. ©2017 Companion Medical. All rights reserved.
SOURCE Companion Medical, Inc.